CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

MP Jogalekar, RL Rajendran, F Khan… - Frontiers in …, 2022‏ - frontiersin.org
Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions

H Ji, C Hu, X Yang, Y Liu, G Ji, S Ge, X Wang… - … and Targeted Therapy, 2023‏ - nature.com
Lymph nodes (LNs) are important hubs for metastatic cell arrest and growth, immune
modulation, and secondary dissemination to distant sites through a series of mechanisms …

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma

N Raje, J Berdeja, YI Lin, D Siegel… - … England Journal of …, 2019‏ - Mass Medical Soc
Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management

JN Brudno, JN Kochenderfer - Blood reviews, 2019‏ - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

N Shah, A Chari, E Scott, K Mezzi, SZ Usmani - Leukemia, 2020‏ - nature.com
Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

T Asmamaw Dejenie, M Tiruneh G/Medhin… - Human vaccines & …, 2022‏ - Taylor & Francis
Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that
is considered a 'living'and self-replicating drug to treat cancer, sometimes resulting in a …

T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma

JN Brudno, I Maric, SD Hartman, JJ Rose… - Journal of Clinical …, 2018‏ - ascopubs.org
Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …

T cell dysfunction and exhaustion in cancer

Z Zhang, S Liu, B Zhang, L Qiao, Y Zhang… - Frontiers in cell and …, 2020‏ - frontiersin.org
Tumor immunotherapy is a promising therapeutic strategy for patients with advanced
cancers. T cells are key mediators of antitumor function that specifically recognize and react …

Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions

A Alnefaie, S Albogami, Y Asiri, T Ahmad… - … in bioengineering and …, 2022‏ - frontiersin.org
Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

CAR T-cell therapy: a new era in cancer immunotherapy

AN Miliotou, LC Papadopoulou - Current pharmaceutical …, 2018‏ - ingentaconnect.com
Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …